Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Sara Bringhen, Francesca Gay, Francesca Donato, Rossella Troia, Roberto Mina & Antonio Palumbo. (2014) Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 23:9, pages 1193-1209.
Read now
Read now
Articles from other publishers (15)
Fangrong Zhang, Qin Yang, Sishi Tang, Siyi Jiang, Qiangqiang Zhao, Jian Li, Cong Xu, Jing Liu & Yunfeng Fu. (2023) CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma. International Journal of Pharmaceutics 643, pages 123241.
Crossref
Crossref
Tingting Jiang, Hui Su, Yanping Li, Yuanlin Wu, Yue Ming, Chen Li, Ruoqiu Fu, Lu Feng, Ziwei Li, Li Li, Rui Ni & Yao Liu. (2022) Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system. Frontiers in Pharmacology 13.
Crossref
Crossref
Pedro Mogollón, Andrea Díaz-Tejedor, Esperanza M. Algarín, Teresa Paíno, Mercedes Garayoa & Enrique M. Ocio. (2019) Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells 8:11, pages 1432.
Crossref
Crossref
Dávid Vrábel, Luděk Pour & Sabina Ševčíková. (2019) The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews 34, pages 56-66.
Crossref
Crossref
Yun Liu, Wen-Jing Huang, Min-Ting Lin, Jia-Jun Li & Jian-Ye Zhang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
207
228
.
Wei Liu, Juan Chen, Archito T. Tamayo, Changgeng Ruan, Li Li, Shouhao Zhou, Chan Shen, Ken H. Young, Jason Westin, Richard E. Davis, Shimin Hu, Leonard J. Medeiros, Richard J. Ford & Lan V. Pham. (2017) Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9:1, pages 346-360.
Crossref
Crossref
Saurabh Chhabra. (2017) Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals 10:4, pages 40.
Crossref
Crossref
J. Ciavarri & S. Langston. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
95
112
.
Kathleen Colson. (2015) Treatment-related symptom management in patients with multiple myeloma: a review. Supportive Care in Cancer 23:5, pages 1431-1445.
Crossref
Crossref
Fernando F. Corrales-Medina, Christa A. Manton, Robert Z. Orlowski & Joya Chandra. (2015) Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leukemia Research 39:3, pages 371-379.
Crossref
Crossref
Fabrizio Accardi, Denise Toscani, Marina Bolzoni, Benedetta Dalla Palma, Franco Aversa & Nicola Giuliani. (2015) Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. BioMed Research International 2015, pages 1-13.
Crossref
Crossref
Lenka Kubiczkova, Ludek Pour, Lenka Sedlarikova, Roman Hajek & Sabina Sevcikova. (2014) Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine 18:6, pages 947-961.
Crossref
Crossref
Antonio Garcia-Gomez, Dalia Quwaider, Miriam Canavese, Enrique M. Ocio, Ze Tian, Juan F. Blanco, Allison J. Berger, Carlos Ortiz-de-Solorzano, Teresa Hernández-Iglesias, Anton C.M. Martens, Richard W.J. Groen, Joaquín Mateo-Urdiales, Susana Fraile, Miguel Galarraga, Dharminder Chauhan, Jesús F. San Miguel, Noopur Raje & Mercedes Garayoa. (2014) Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. Clinical Cancer Research 20:6, pages 1542-1554.
Crossref
Crossref
Antonio Garcia-Gomez. (2014) Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World Journal of Stem Cells 6:3, pages 322.
Crossref
Crossref
Alessandro Allegra, Andrea Alonci, Demetrio Gerace, Sabina Russo, Vanessa Innao, Laura Calabrò & Caterina Musolino. (2014) New orally active proteasome inhibitors in multiple myeloma. Leukemia Research 38:1, pages 1-9.
Crossref
Crossref